RE-EMERGENCE OF POSITIVE SYMPTOMS OF SCHIZOPHRENIA DURING THE COURSE OF TREATMENT WITH RISPERIDONE

Sir,
We would like to respond to the article titled "Re-emergence of positive symptoms of schizophrenia during the course of treatment with risperidone" (Bajaj et al.) , that was published in the Indian Journal of Psychiatry, Vol.41/No.2/April, 1999. It was quite interesting to note that these authors had observed a re-emergence of positive symptoms in 7 patients, out of 30 patients of schizophrenia treated with risperidone. We would like to present a brief report of a similar phenomenon observed in one schizophrenic patient undergoing treatment in the Dept. of Psychiatry, JIPMER Hospital, Pondicherry.
Mr.X, a 28-yr. old unmarried male was hospitalized in August,1999 with an ICD-10 diagnosis of residual schizophrenia. His illness had, by then, run a chronic unremitting course for three years, with a definite progression from an initial brief phase characterised by overt positive symptoms to the second and chronic stage, comprising all the typical negative symptoms such as avolition, apathy, social withdrawal, anhedonia, blunted affect and a gross reduction in speech output. A detailed cross-sectional evaluation soon after admission did not reveal any disorder of form of thought, delusions, thought-alienation phenomena or perceptual disturbances. Patient's baseline BPRS score was 24. Baseline PANSS profile was as follows : Positive syndrome score=11, negative syndrome score=46, general psychopathology score=39. Risperidone was initiated at a dose of 2 mg/day and gradually incraesed to a total of 8 mg/day in 2 divided doses. After 2 weeks of treatment with 8 mg of risperidone, interesting changes were observed in the patient's clinical profile and his scores on BPRS and PANSS. Total BPRS score had increased to 26, while the PANSS scores were as follows : Positive syndrome score=27, negative syndrome score=27, general psychopathology score=39. These rating scale scores correlated with clinically observed worsening of positive symptoms, especially conceptual disorganization and grandiosity and improvement in negative symptoms.
This unusual and unexpected observation leads us to speculate on the rather unique receptor binding properties of risperidone (5HT 2 +D 2 receptor antagonism), the relationship between the roles of serotonin and dopamine in schizophrenia and also the possibility of this phenomenon being essentially due to an idiosyncratic neurochemical profile in this particular patient. 5HT 2 antagonists have been shown to have an antipsychotic effect, particularly on the negative symptom cluster (Bleich et a!.,1988) . Research has also shown that risperidone is effective against both the positive and the negative symptoms of schizophrenia (Marder & Meibach,1994) . Agarwal et al.(1998) had investigated the response of Indian schizophrenic patients to risperidone and observed a reduction in score in both the positive syndrome scale and the negative syndrome scale of PANSS. Based on the available literature, it is possible to explain the beneficial effect that risperidone has had on the negative symptoms of our patient. But, the apparent re-emergence/worsening of positive symptoms during treatment with risperidone is a strange phenomenon that seems to have no concrete explanation as yet. Bajaj et al.(1999) nave suggested that risperidone's antiserotonergic activity may possibly potentiate dopamine release at the mesolimbic region, counteracting the primary anti-psychotic activity, resulting in a re-emergence of positive symptoms. This is quite a plausible and interesting hypothesis that needs to be clarified through further research, especially because risperidone is a highly effective anti-psychotic drug that has occupied an important position in the management of schizophrenia.
